PMID- 33081726
OWN - NLM
STAT- MEDLINE
DCOM- 20210201
LR  - 20210201
IS  - 1471-2261 (Electronic)
IS  - 1471-2261 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Oct 20
TI  - Increased osteoprotegerin level is associated with impaired cardiovagal 
      modulation in type-2 diabetic patients treated with oral antidiabetic drugs.
PG  - 453
LID - 10.1186/s12872-020-01729-1 [doi]
LID - 453
AB  - BACKGROUND: An increased osteoprotegerin (OPG) level has been reported in both 
      type-2 diabetes mellitus (T2DM) and cardiovascular diease (CVD) that are linked 
      to sympathovagal imbalance (SVI). We explored the link of osteoprotegerin with 
      cardiovagal modulation in T2DM. METHODS: We assessed fasting serum OPG, 
      high-sensitive C-reactive protein (hsCRP), glucose, insulin and lipid profile in 
      patients having T2DM receiving oral antidiabetic drugs (OAD) (n = 42) compared 
      with age, gender and body composition-matched healthy participants without 
      diabetes (n = 42). Rate pressure product (RPP), spectral indices of heart rate 
      variability (HRV) and body composition were recorded in both the groups. 
      Association of HOMA-IR and OPG with various parameters were assessed. RESULTS: 
      Osteoprotegerin, HOMA-IR, hsCRP, coronary lipid risk factor were significantly 
      increased, markers of cardiovagal modulation (TP, SDNN, RMSSD) were considerably 
      decreased, ratio of low-frequency to high-frequency (LH-HF ratio), the indicator 
      of SVI, and RPP, the marker of myocardial work stress were significantly higher 
      in patients with diabetes, suggesting an overall elevated CVD risks in them. 
      HOMA-IR was correlated with RMSSD, lipid risk factors and OPG. Rise in OPG was 
      correlated with decreased cardiovagal modulation in patients with diabetes. There 
      was significant contribution of OPG in decreasing TP, suggesting impaired 
      cardiovagal modulation. CONCLUSION: T2DM patients receiving OAD had higher 
      cardiometabolic risks compared to age, gender and body composition-matched 
      healthy individuals. Increased level of OPG is linked to decreased cardiovagal 
      modulation in T2DM patients.
FAU - Jasmine, M R
AU  - Jasmine MR
AD  - Department of Biochemistry, Jawaharlal Institute of Postgraduate Medical 
      Education and Research (JIPMER), Puducherry, 605 006, India.
FAU - Nanda, Nivedita
AU  - Nanda N
AUID- ORCID: 0000-0002-8887-8357
AD  - Department of Biochemistry, Jawaharlal Institute of Postgraduate Medical 
      Education and Research (JIPMER), Puducherry, 605 006, India. 
      drnnivedita@gmail.com.
FAU - Sahoo, Jayaprakash
AU  - Sahoo J
AD  - Department of Endocrinology, Jawaharlal Institute of Postgraduate Medical 
      Education and Research, Puducherry, India.
FAU - Velkumary, S
AU  - Velkumary S
AD  - Department of Physiology, Jawaharlal Institute of Postgraduate Medical Education 
      and Research, Puducherry, India.
FAU - Pal, G K
AU  - Pal GK
AD  - Department of Physiology, Jawaharlal Institute of Postgraduate Medical Education 
      and Research, Puducherry, India.
LA  - eng
GR  - JIP/Res/Intra-MSc/02//2015-16/Intramural/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201020
PL  - England
TA  - BMC Cardiovasc Disord
JT  - BMC cardiovascular disorders
JID - 100968539
RN  - 0 (Biomarkers)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Osteoprotegerin)
RN  - 0 (Sulfonylurea Compounds)
RN  - 0 (TNFRSF11B protein, human)
RN  - 6KY687524K (glimepiride)
RN  - 9100L32L2N (Metformin)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Biomarkers/blood
MH  - Cardiometabolic Risk Factors
MH  - Case-Control Studies
MH  - Diabetes Mellitus, Type 2/blood/*drug therapy/physiopathology
MH  - Female
MH  - Heart/*innervation
MH  - Humans
MH  - Hypoglycemic Agents/*administration & dosage/adverse effects
MH  - India
MH  - Male
MH  - Metformin/*administration & dosage/adverse effects
MH  - Middle Aged
MH  - Osteoprotegerin/*blood
MH  - Risk Assessment
MH  - Sulfonylurea Compounds/*administration & dosage/adverse effects
MH  - Treatment Outcome
MH  - Up-Regulation
MH  - Vagus Nerve/*physiopathology
PMC - PMC7574185
OTO - NOTNLM
OT  - Cardiometabolic risks
OT  - Cardiovagal modulation
OT  - Heart rate variability
OT  - Osteoprotegerin
OT  - Sympathovagal imbalance
OT  - Type-2 diabetes mellitus
COIS- The authors declare that there is no competing interest.
EDAT- 2020/10/22 06:00
MHDA- 2021/02/02 06:00
PMCR- 2020/10/20
CRDT- 2020/10/21 05:37
PHST- 2020/02/10 00:00 [received]
PHST- 2020/10/06 00:00 [accepted]
PHST- 2020/10/21 05:37 [entrez]
PHST- 2020/10/22 06:00 [pubmed]
PHST- 2021/02/02 06:00 [medline]
PHST- 2020/10/20 00:00 [pmc-release]
AID - 10.1186/s12872-020-01729-1 [pii]
AID - 1729 [pii]
AID - 10.1186/s12872-020-01729-1 [doi]
PST - epublish
SO  - BMC Cardiovasc Disord. 2020 Oct 20;20(1):453. doi: 10.1186/s12872-020-01729-1.